Design, Synthesis and Biological Activity Evaluation of Arylpiperazine Derivatives for the Treatment of Neuropathic Pain

被引:8
作者
Chen, Yin [1 ]
Wang, Guan [2 ]
Xu, Xiangqing [3 ]
Liu, Bi-Feng [1 ]
Li, Jianqi [2 ]
Zhang, Guisen [1 ,3 ]
机构
[1] Huazhong Univ Sci & Technol, Dept Syst Biol, Wuhan 430074, Peoples R China
[2] Shanghai Inst Pharmaceut Ind, Shanghai 200437, Peoples R China
[3] Jiangsu Nhwa Pharmaceut Corp Ltd, Xuzhou 221009, Jiangsu, Peoples R China
关键词
arylpiperazine; antinociceptive; neuropathic pain; spared nerve injury; chronic constriction injury; EFFICACY 5-HT1A AGONIST; SPARED NERVE INJURY; PHARMACOLOGICAL CHARACTERIZATION; RECEPTOR AFFINITY; RAT MODEL; ANTAGONISTS; ANALGESIA; MORPHINE; F-13640; ANTIDEPRESSANTS;
D O I
10.3390/molecules16075785
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this work, a series of arylpiperazine derivatives were synthesized and screened by in vivo pharmacological trials. Among the tested compounds, 2-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)-1-phenylethanone (18) and 2-(4-(2,3-dimethylphenyl)piperazin-1-yl)-1-phenylethanone (19) exhibited potent analgesic activities in both the mice writhing and mice hot plate tests. They showed more than 70% inhibition relative to controls in the writhing test, and increased latency by 116.0% and 134.4%, respectively, in the hot plate test. Furthermore, compound 18 was also active in the models of formalin pain and neuropathic pain without sedative side effects.
引用
收藏
页码:5785 / 5806
页数:22
相关论文
共 47 条
[1]  
Attal N, 2010, EUROPEAN NEUROLOGICA, V2, P25
[2]   Profound, non-opioid analgesia produced by the high-efficacy 5-HT1A agonist F 13640 in the formalin model of tonic nociceptive pain [J].
Bardin, L ;
Tarayre, JP ;
Malfetes, N ;
Koek, W ;
Colpaert, FC .
PHARMACOLOGY, 2003, 67 (04) :182-194
[3]   A PERIPHERAL MONONEUROPATHY IN RAT THAT PRODUCES DISORDERS OF PAIN SENSATION LIKE THOSE SEEN IN MAN [J].
BENNETT, GJ ;
XIE, YK .
PAIN, 1988, 33 (01) :87-107
[4]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[5]   NR2B selective NMDA antagonists:: The evolution of the ifenprodil-type pharmaeophore [J].
Borza, Istvan ;
Domany, Gyorgy .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (07) :687-695
[6]   New serotonin 5-HT2A, 5-HT2B, and 5-HT2c receptor antagonists:: Synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones [J].
Brea, J ;
Rodrigo, J ;
Carrieri, A ;
Sanz, F ;
Cadavid, MI ;
Enguix, MJ ;
Villazón, M ;
Mengod, G ;
Caro, Y ;
Masaguer, CF ;
Raviña, E ;
Centeno, NB ;
Carotti, A ;
Loza, MI .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (01) :54-71
[7]   Current and emerging targets to treat neuropathic pain [J].
Butera, John A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (11) :2543-2546
[8]   Discovery of a New Class of Potential Multifunctional Atypical Antipsychotic Agents Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors: Design, Synthesis, and Effects on Behavior [J].
Butini, Stefania ;
Gemma, Sandra ;
Campiani, Giuseppe ;
Franceschini, Silvia ;
Trotta, Francesco ;
Borriello, Marianna ;
Ceres, Nicoletta ;
Ros, Sindu ;
Coccone, Salvatore Sanna ;
Bernetti, Matteo ;
De Angelis, Meri ;
Brindisi, Margherita ;
Nacci, Vito ;
Fiorini, Isabella ;
Novellino, Ettore ;
Cagnotto, Alfredo ;
Mennini, Tiziana ;
Sandager-Nielsen, Karin ;
Andreasen, Jesper Tobias ;
Scheel-Kruger, Jorgen ;
Mikkelsen, Jens D. ;
Fattorusso, Caterina .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (01) :151-169
[9]   QUANTITATIVE ASSESSMENT OF TACTILE ALLODYNIA IN THE RAT PAW [J].
CHAPLAN, SR ;
BACH, FW ;
POGREL, JW ;
CHUNG, JM ;
YAKSH, TL .
JOURNAL OF NEUROSCIENCE METHODS, 1994, 53 (01) :55-63
[10]   Neuropathic agents and pain. New strategies [J].
Chong, M. S. ;
Brandner, B. .
BIOMEDICINE & PHARMACOTHERAPY, 2006, 60 (07) :318-322